Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

Caio Max Rocha Lima, Mark R. Green, Robert Rotche, Wilson H. Miller, G. Mark Jeffrey, Laura A. Cisar, Adele Morganti, Nicoletta Orlando, Gabriela Gruia, Langdon L. Miller

Research output: Contribution to journalArticle

521 Scopus citations

Fingerprint Dive into the research topics of 'Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate'. Together they form a unique fingerprint.

Medicine & Life Sciences